Laval, Canada-based Valeant Pharmaceuticals entered into a licensing agreement with Waltham, Mass.-based EyeGate Pharmaceuticals for the EyeGate II Delivery System and EGP-437 combination product candidate.
Here's what you should know.
1. Providers use the products to treat ocular surgery patients' postoperative pain and inflammation.
2. Valeant secured a product license in 2015.
3. Valeant CEO Joseph Papa said, "We are pleased to extend our relationship with EyeGate, and to obtain the global commercial and manufacturing rights to the EyeGate II Delivery System for the indication of postoperative inflammation and pain in ocular surgery patients."
4. Mr. Papa said the products have "significant potential" as part of the Bausch + Lomb, Valeant's eye care division.
More articles on improving health:
Healthcare data breaches up 40% in 2016, hitting 15.9M patient records: 5 key points
Protesters meet Republicans at town halls across the country, spar over healthcare
5 legislative changes for ASC leaders to note — Feb. 22, 2017